Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short-term Investments (2016 - 2021)

Aytu Biopharma has reported Short-term Investments over the past 6 years, most recently at $252000.0 for Q3 2021.

  • Quarterly Short-term Investments changed 0.0% to $252000.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $252000.0 through Sep 2021, changed 0.0% year-over-year, with the annual reading at $252000.0 for FY2021, 0.4% changed from the prior year.
  • Short-term Investments was $252000.0 for Q3 2021 at Aytu Biopharma, roughly flat from $252000.0 in the prior quarter.
  • Over five years, Short-term Investments peaked at $252000.0 in Q3 2020 and troughed at $75214.0 in Q2 2017.
  • The 5-year median for Short-term Investments is $250500.0 (2019), against an average of $195549.0.
  • Year-over-year, Short-term Investments tumbled 92.78% in 2017 and then surged 150.83% in 2019.
  • A 5-year view of Short-term Investments shows it stood at $75214.0 in 2017, then soared by 33.25% to $100225.0 in 2018, then surged by 150.83% to $251396.0 in 2019, then increased by 0.24% to $252000.0 in 2020, then changed by 0.0% to $252000.0 in 2021.
  • Per Business Quant, the three most recent readings for AYTU's Short-term Investments are $252000.0 (Q3 2021), $252000.0 (Q2 2021), and $252000.0 (Q4 2020).